.Long-term Debt and Solvency Analysis
Difficulty: Beginner
Solvency ratios also known as long-term debt ratios measure a company's ability to meet long-term obligations.
Ratios (Summary)
Bristol-Myers Squibb Co., debt and solvency ratios
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| | Debt to equity | |||||
| | Debt to capital | |||||
| | Interest coverage |
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
| Ratio | Description | The company |
|---|---|---|
| Debt-to-equity ratio | A solvency ratio calculated as total debt divided by total shareholders' equity. | Bristol-Myers Squibb Co.'s debt-to-equity ratio improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017. |
| Debt-to-capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders' equity. | Bristol-Myers Squibb Co.'s debt-to-capital ratio improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017. |
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.'s interest coverage ratio improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017. |
Debt to Equity
Bristol-Myers Squibb Co., debt to equity calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| | Short-term debt obligations | |||||
| | Long-term debt, excluding current portion | |||||
| | Total debt | |||||
| | Total Bristol-Myers Squibb Company shareholders' equity | |||||
| Ratio | ||||||
| | Debt to equity1 | |||||
| Benchmarks | ||||||
| Debt to Equity, Competitors | ||||||
| Abbott Laboratories | ||||||
| AbbVie Inc. | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Celgene Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
2017 Calculations
1 Debt to equity = Total debt ÷ Total Bristol-Myers Squibb Company shareholders' equity
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Debt-to-equity ratio | A solvency ratio calculated as total debt divided by total shareholders' equity. | Bristol-Myers Squibb Co.'s debt-to-equity ratio improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017. |
Debt to Capital
Bristol-Myers Squibb Co., debt to capital calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| | Short-term debt obligations | |||||
| | Long-term debt, excluding current portion | |||||
| | Total debt | |||||
| | Total Bristol-Myers Squibb Company shareholders' equity | |||||
| | Total capital | |||||
| Ratio | ||||||
| | Debt to capital1 | |||||
| Benchmarks | ||||||
| Debt to Capital, Competitors | ||||||
| Abbott Laboratories | ||||||
| AbbVie Inc. | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Celgene Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
2017 Calculations
1 Debt to capital = Total debt ÷ Total capital
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Debt-to-capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders' equity. | Bristol-Myers Squibb Co.'s debt-to-capital ratio improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017. |
Interest Coverage
Bristol-Myers Squibb Co., interest coverage calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| | Net earnings attributable to BMS | |||||
| | Add: Net income attributable to noncontrolling interest | |||||
| | Add: Income tax expense | |||||
| | Add: Interest expense | |||||
| | Earnings before interest and tax (EBIT) | |||||
| Ratio | ||||||
| | Interest coverage1 | |||||
| Benchmarks | ||||||
| Interest Coverage, Competitors | ||||||
| Abbott Laboratories | ||||||
| AbbVie Inc. | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Celgene Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
2017 Calculations
1 Interest coverage = EBIT ÷ Interest expense
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.'s interest coverage ratio improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017. |
